MOBYLIFE TO SUSPEND INTEREST PAYMENTS ON ITS NOTES PENDING THE OUTCOME OF DISCUSSIONS WITH ITS CREDITOR COMMITTEE
Comunicato Precedente
Comunicato Successivo
COMPANY ANNOUNCEMENT
MOBYLIFE TO SUSPEND INTEREST PAYMENTS ON ITS NOTES PENDING THE OUTCOME OF DISCUSSIONS WITH ITS CREDITOR COMMITTEE
Copenhagen, 22 February 2018
Reference is made to the company announcement dated 9 February 2018 of Mobylife Holding A/S ("Mobylife"), announcing its intention to hold discussions with the holders of its senior secured notes (ISIN SE0005936382) (the "Notes") in relation to a potential amendment to Mobylife's capital structure.
Mobylife can confirm that it has commenced discussions with a committee of Noteholders whose holdings represent nearly 50 per cent. of the total outstanding nominal amount of the Notes, and those discussions are currently ongoing.
Given the ongoing discussions, Mobylife has decided that it would not be appropriate at this stage to make the payment of interest due under the terms and conditions of the Notes on 23 February 2018, and has suspended such payment pending a conclusion of discussions with the Noteholder committee. The outcome of such discussions will be announced by Mobylife in due course.
For further information:
For further information, enquiries should be directed to:
THE AGENT:
Intertrust (Sweden) AB
Anna Litewka
Email: [email protected]
Tel: +46 (0)8 402 72 11
Mobylife Holding A/S
Jakob Kraglund, CEO
Email: [email protected]
Tel: +45 2392 3724
Jacob Halberg, CFO
Email: [email protected]
Tel: +45 5314 4133
Catacap Management A/S
Vilhelm Hahn-Petersen, Partner
Email: [email protected]
Tel: +45 2632 6420
This information is information that Mobylife Holding A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.00 CET on 22 February 2018.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Mobylife Holding A/S via Globenewswire
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti